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Abstract
Background: Cushing’s disease is an ACTH-producing pituitary adenoma, and the primary treatment is microscopic
or endoscopic transsphenoidal selective adenectomy. The aims of the present study were to evaluate whether the
early postoperative S-cortisol level can serve as a prognostic marker for short- and long-term remission, and
retrospectively review our own short and long term results after surgery for Cushing’s disease.
Methods: This single centre, retrospective study consists of 19 consecutive patients with Cushing’s disease who
underwent transsphenoidal surgery. S-cortisol was measured every 6 h after the operation without any
glucocorticoid replacement. We have follow-up on all patients, with a mean follow-up of 68 months.
Results: At the three-month follow-up, 16 patients (84 %) were in remission; at 12 months, 18 (95 %) were in
remission and at the final follow-up (mean 68 months), 13 (68 %) were in remission. Five-years recurrence rate was
26 %. The mean postoperative S-cortisol nadir was significantly lower in the group of patients in remission than in
the non-remission group at 3 months, but there was no difference between those in long-term remission
compared to those in long-term non-remission. The optimal cut-off value for classifying 3-month remission was
74 nmol/l.
Conclusion: We achieved a 95 % 1-year remission rate with transsphenoidal surgery for Cushing’s disease in this
series of consecutive patients. However, the 5-year recurrence rate was 26 %, showing the need for regular clinical
and biochemical controls in this patient group. The mean postoperative serum-cortisol nadir was significantly lower
in patients in remission at 3 months compared to patients not in remission at 3 months, but a low postoperative
S-cortisol did not predict long-term remission.
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Background
Cushing’s disease is caused by a pituitary adenoma that
hyper secretes adrenocorticotropic hormone (ACTH),
and it was first described by Harvey Cushing in 1932 [1].
Untreated Cushing’s disease is associated with significant
morbidity and mortality [2]. The primary treatment is
transsphenoidal selective adenectomy, either micro-
scopic or endoscopic. The remission rate after selective
microadenectomy varies greatly between 55 and 95 %
[3–8], and the recurrence rate after initial remission of
Cushing’s disease is reported to be in the range 5–38 %
10 years after surgery [9, 10]. A second transsphenoidal
surgery is an option for patients who are not initially
cured or with recurrent disease, but it is associated with
a lower success rate than primary surgery and more
surgery-related complications [11, 12].
There is no international consensus on the definition
of remission for Cushing’s disease after transsphenoidal
surgery. The large variations in the remission rates after
surgery might reflect this lack of consensus. The most
commonly used remission criteria are the following:
clinical resolution of symptoms, normal low dose dexa-
methasone suppression test (DST) (2 mg/d for 48 h),
normal urinary free cortisol level and normal late night
salivary cortisol [13].
Recent publications on Cushing’s disease have suggested
that early postoperative serum-cortisol (S-cortisol) levels
can predict remission [14–16]. The main aim of the
present study was to evaluate the role of the early postop-
erative S-cortisol level as a prognostic marker for short-
and long-term remission.
Methods
This is a single centre, retrospective study of 19 con-
secutive patients with Cushing’s disease who underwent
operation performed by a single neurosurgeon (JRP) at
Oslo University Hospital (OUS), Oslo, Norway between
2003 and 2008.
Preoperative diagnostic work-up
The initial endocrine evaluation was performed at a spe-
cialised endocrinology centre at OUS. Patients with clin-
ical features and a baseline laboratory test indicative of
Cushing’s syndrome were evaluated with 24-h urinary
free cortisol, late night salivary cortisol, 48-h, low dose
dexamethasone suppression test (DST) (2 mg/d for 48 h)
and corticotrophin-releasing hormone (CRH) test. Once
the diagnosis of ACTH-dependent Cushing’s syndrome
was established [17], a multidisciplinary team, consisting
of an endocrinologist, radiologist, oncologist and neuro-
surgeon, discussed the patients and established the indica-
tion for surgery. All patients underwent 1.5 tesla MRI
scans after a dedicated pituitary protocol, and those with
initial normal scans were investigated with dynamic
sequences. When indicated, inferior petrosal sinus sam-
pling (IPSS) was performed to establish the diagnosis of
Cushing’s disease. When IPSS was performed ACTH
was measured both before and after intravenous CRH
administration. A central-to-peripheral ratio of more
than two before CRH administration, or more than
three after, was interpreted as positive for Cushing’s
disease [18].
Surgical technique
All patients underwent operation while under general
anaesthesia, with total intravenous anaesthesia in most
cases. The standard microsurgical endonasal transsep-
tal approach was used prior to 2006. Through the
right nostril, an incision was made in the anterior part
of the septum, and the mucosa was dissected from the
septal cartilage and bone. The anterior wall of the
sphenoid sinus was opened bilaterally and any septum
in the sphenoid sinus was removed as necessary. The
floor of the sella was opened with a high-speed drill.
The tumour was removed with standard instruments,
such as curettes, suction and micro forceps. After
tumour removal, the floor of the sella was recon-
structed with two layers of Neuropatch® (BBraun,
Tutlingen, Germany) and the septal bone to recon-
struct the floor of the sella, which was sealed with fi-
brin glue and gelfoam. In a few patients with small
nostrils (paediatric cases), a sublabial approach was
performed. After 2006, the endoscopic endonasal
transsphenoidal approach became standard procedure.
One or both nostrils were entered according to the
available space and need for exposure during the sur-
gery. We used standard Storz endoscopes (Karl Storz
GmbH & Co, Tuttlingen, Germany) (180/4 mm), with
00, 300 and 450 angulations coupled to cameras, in the
later period of the study to HD cameras. In the first
cases, we used a fixed endoscope support, whereas in
the later cases, the endoscope was handled freehand
to increase flexibility during surgery. Image-guided
navigation (BrainLab AG, Feldkirchen, Germany) was
used in some procedures. Tumour resection was per-
formed with standard surgical instruments, such as
dissectors, curettes, suction and micro forceps,
dependent on the tumour size and firmness. In tu-
mours with parasellar extension, we routinely used an
ultrasonic Doppler probe (Mitzhuo Medical Inc, Tokyo,
Japan) to localise the internal carotid artery. The surgi-
cal corridor was closed with two layers of Duragen
(Integra LifeScience Corporation, New Jersey, USA) and
a Porex plate (Porex Corporation, Atlanta, Georgia,
USA) for rigid reconstruction of the sellar floor. One
dose of cefalotin was administered intravenously before
the operation. No glucocorticoids were given pre- or
perioperatively.
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Surgery-related complications
The following complications were recorded: mortality,
CSF-leakage, vascular injury, infection, new neurological
deficits and new hormone deficiencies, including ADH
deficiency.
Endocrine evaluation immediately after surgery and
before discharge
No exogenous glucocorticoids were given postopera-
tively, and the serum levels of cortisol were measured
every 6 h at fixed hours (12, 18, 24, 06, 12, and so forth),
starting immediately after the end of surgery. If the pa-
tient showed clinical symptoms or signs of hypocortiso-
laemia (headache, nausea, fatigue, low serum sodium,
fever, and hypotension) or had S-cortisol levels below
100 nmol/l, exogenous glucocorticoids were adminis-
tered, initially per oral cortisone acetate 100 mg × 2, and
no further measurements of S-cortisol was done. Pa-
tients without clinical symptoms of hypocortisolaemia
who did not reach a nadir of 100 nmol/dl were pre-
scribed exogenous glucocorticoids at discharge from the
hospital for use as required. The S-cortisol levels were
measured for 1 to 4 days after surgery. We used a S-
cortisol nadir of <50 nmol/l, <100 nmol/l and
<200 nmol/l to predict remission at the different end-
points, and we calculated the sensitivity and specificity
at each time point.
Definitions of remission and recurrence
Remission was defined as relief from clinical symptoms,
urinary free cortisol below threshold, late night salivary
cortisol below threshold, and suppression to <50 nmol/l
of S-cortisol on 1 mg overnight or 2 mg/D, 48 h DST.
The definition of recurrence is difficult, and it must be
stressed that this is an integrated clinical and biochem-
ical assessment. Relapse of clinical symptoms, such as
cutaneous symptoms (red striae, easy bruising and thin
skin), central obesity and proximal muscle weakness, are
strong indicators of disease recurrence, but these symp-
toms often appear late and long after biochemical tests
indicate relapse from the disease. We used elevated
morning S-cortisol, elevated late night salivary cortisol,
elevated 24 h urinary free cortisol, elevated morning
serum cortisol and inadequate suppression of cortisol
after DST as the criteria for recurrence.
Follow-up
Patients were seen in the outpatient ward of the section of
specialised endocrinology at 6 weeks, 3 months and
6 months after surgery and thereafter at least once a year.
Statistical analysis
The data are summarised with counts, percentages, means
and medians as appropriate. T-tests robust for unequal
variances are used. Due to the correlational structure of
the repeated intra-individual cortisol measurements, the
confidence intervals of Figs. 2 and 3 were calculated ac-
cording to Morey [19]. The time trend of cortisol was in-
vestigated using logistic regression and the area under the
curve (AUC) of the cortisol values over time, nadir values
and slope until nadir. The nadir value was further investi-
gated as a classifier for remission using receiver-
operating-characteristics (ROC) curves. The optimal cut-
off was calculated by finding the maximum Youden index
over all nadir values. The confidence interval for the AUC
in the ROC was calculated using bootstrapping tech-
niques. A confidence interval for the ROC AUC excluding
0.5 was considered significant.
Excel 2010 (Microsoft) and R version 3.0.3 [20] were
used for all statistical analysis. P-values <0.05 were con-
sidered significant.
Results
Nineteen consecutive patients with clinically and bio-
chemically verified Cushing’s disease were included in
this study. There were 13 females (68 %). The median
age was 38.0 years (range 13–66 years). Three patients
had undergone a previous operation and had biochem-
ical and neuroradiological residual tumour. They were
primarily operated in 1995, 1999 and 2000. All patients
are represented only once in this material.
Preoperative MRI showed a microadenoma in 13 pa-
tients (68 %), macroadenoma in two patients (11 %) and
no tumour in four patients (21 %). In cases without vis-
ible tumour, the diagnosis of Cushing’s disease was based
on demonstrating ACTH-dependent Cushing’s syn-
drome in combination with positive IPSS. Details on the
pre and intraoperative findings are given in Table 1.
All patients underwent transsphenoidal surgery. Neuro-
pathological examination verified an ACTH-producing
adenoma in 11 of the 19 patients (58 %). In the remaining
eight patients, either an insufficient amount of material
was obtained for reaching a confident conclusion or the
pathologist did not identify the sample as tumour.
At the 3-month follow-up, 84 % were in remission; at
the 12-month follow-up, 95 % were in remission and at
the final follow-up (68 months), 68 % were in remission.
A summary of the endocrinological outcome at 3 and
12 months as well as in the long-term is given in Table 2.
The format of this table is the same as in the publication
by Starke et al., facilitating meta-analyses [9]. The indi-
vidual S-cortisol curves of all patients after surgery are
plotted in Fig. 1. There is considerable inter-individual
variation, but in the first three postoperative days, there
was a tendency towards lower values as the time from
surgery increased. In Fig. 2, the postoperative S-cortisol
values were stratified according to remission at 3 months.
Using paired T-tests, there are significant differences
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between the curves at 54 and 60 h after surgery, but
statistical curve analysis did not reveal any significant
difference between the curves. In Fig. 3, the postopera-
tive S-cortisol values are stratified according to remis-
sion at the last follow-up. The postoperative S-cortisol
values do not predict long-term remission at any time-
point. In Table 3, the pre- and intra-operative variables
are correlated with short- and long-term remission. The
mean S-cortisol nadir is significantly lower in the group
of patients in remission at 3 months compared to the
group of patients not in remission at 3 months. No such
correlation was seen for long-term remission.
In Fig. 4, a ROC curve is displayed, demonstrating
the performance for the nadir of postoperative S-
cortisol in classifying both the 3-months and long-
term remission. The areas under the curve for the
ROC curves are 0.86 (95 % CI (0.67, 1)) and 0.69
(95 % CI (0.44, 0.93), respectively. Therefore, the per-
formance of the postoperative S-cortisol nadir in clas-
sifying the 3-month and long-term remission was
significant and non-significant, respectively. The opti-
mal cut-off value for classifying 3-month remission is
74 nmol/l.
A positive histology, positive preoperative MRI or size
of tumour showed no correlation with remission at
3 months or in the long-term.
Complications
Three patients were substituted for new postoperative
hormonal deficiencies; two patients had central
hypothyroidism (patient 1 and 19) and one had gonado-
trophic deficiency (patient 13). None of the following
Table 1 Pre and intraoperative findings and postoperative result
Pt MRI Histology Result Cortisol substitution
3 months 12 months Last follow-up 3 months 12 months Last follow-up
1 Neg Adenoma Remission Remission Remission Yes No No
2 Microa Adenoma Remission Remission Remission Yes Yes No
3 Macrob Adenoma Remission Remission Remission No No No
4 Micro No tumour Persistent Remission Remission No No No
5 Neg No tumour Remission Remission Remission Yes Yes No
6 Micro No tumour Remission Remission Recurrence No No No
7 Macro Adenoma Remission Remission Recurrence Yes No No
8 Micro Adenoma Remission Remission Remission Yes Yes No
9 Micro Adenoma Remission Remission Remission Yes Yes Yes
10 Micro Adenoma Remission Remission Remission Yes Yes No
11 Micro Adenoma Remission Remission Remission Yes No No
12 Micro No tumour Remission Remission Remission Yes Yes Yes
13 Micro Adenoma Remission Remission Remission Yes No No
14 Neg No tumour Remission Remission Recurrence No No No
15 Micro Adenoma Remission Remission Recurrence No No No
16 Micro No tumour Remission Remission Recurrence Yes No No
17 Micro No tumour Persistent Remission Remission No No No
18 Neg No tumour Persistent Persistent Persistent No No No
19 Micro Adenoma Remission Remission Remission Yes Yes Yes
amicro < 10 mm
bmacro ≥ 10 mm
Table 2 Summarised outcome data
Outcome Follow-up Follow-up Last follow-up
3-month 12-month (mean 68 months)
n = 19, n (% of n) n = 19, n (% of n) n = 19, n (% of n)
Overall remission 16 (84) 18 (95) 13 (68)
Hypocortisolaemia 12 (63) 7 (37) 3 (16)
Eucortisolaemia 4 (21) 11 (58) 10 (52)
Hypercortisolaemia 3 (16) 1 (5) 6 (32)
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were present: cerebrospinal fluid leak, vascular injury,
infection, new neurological deficits and surgical mortality.
Discussion
The overall remission rate in this study of 19 patients
with clinically and biochemically verified Cushing’s dis-
ease was 84 % at 3 months, 95 % at 12 months and 68 %
at 68 months follow-up, which is in agreement with
other recent published series [9, 21]. A low immediate
postoperative S-cortisol value was a predictor for short-
term remission but not for long-term remission, which
is in contrast to other published studies [9, 14, 16], the
reason for this might be that we have long-term follow-
up on all patients and a relatively high rate of late
recurrences.
Surgical outcome
The lack of international consensus on the definition of
cure after transphenoidal surgery for Cushing’s disease
makes the interpretation of reported outcome figures
difficult. Most authors use the clinical resolution of
symptoms and one or more of the biochemical parame-
ters of normalisation of 24 h urinary free cortisol levels,
low late-night saliva cortisol, normal midnight serum
cortisol or suppression of cortisol after low-dose dexa-
methasone test. Due to this lack of consensus and the het-
erogeneity of patient populations, there is considerable
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Fig. 1 Individual curves of the serum cortisol levels at fixed, 6-h intervals after transsphenoidal surgery for Mb. Cushing
Fig. 2 Mean postoperative S-cortisol values at given hours after surgery. The dense line represents patients who are not in remission at the 3-month
follow-up, and the dotted line represents patients in remission at the 3-month follow-up. P< 0.05 at 54 and 60 h after surgery. Units on the y-axis is nmol/l
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variation in the reported immediate postoperative remis-
sion rate, ranging from 55 to 95 % [3–8, 22] The best re-
sults are obtained in patients with non-invasive
microadenomas with cure rates as high as 93 %, and with
a marked reduction in the remission rate with increasing
tumour diameter and extrasellar extension [23]. Our re-
sults of 84 % in remission at 3 months and 95 % in
remission at 1 year are in accordance with the litera-
ture. It is worth noting that all of our patients com-
pleted follow-up, while in other published series, up
to 30 % of the patients were lost to follow-up, which
may have biased the results [9, 10].
In this study, with a mean follow-up of 5.7 years
(68 months), five out of 19 patients had a late recur-
rence. This high recurrence rate (26 %) may represent
the “natural, but underreported, history of the disease”
or the consequence of our surgical practise. Few compli-
cations were recorded in this series, with zero surgical
complications and three patients with new hormonal
deficits, which may reflect a cautious attitude during re-
section or extirpation of the tumour. On the other hand,
long-term follow-up was performed on all patients and
will tend to give a higher recurrence rate. In a large
study on late recurrences of Cushing’s disease after ini-
tial successful surgery, 215 patients were followed for a
mean of 45 months, and the actuarial recurrence rate
after 5 years was 25.5 % [10]. Atkinson et al. reported a
9.6-year recurrence rate of 22 % [24]. In a newly pub-
lished report, the recurrence rate was 65.6 % with
follow-up of 14 ± 10 years, whereas mean time to recur-
rence was 2.4 ± 1.7 years [25].
The reported long-term recurrence rates for other
endocrine active pituitary adenomas, like growth hor-
mone secreting tumours, are considerably lower, ranging
from 2 to 6 % [26, 27]. The higher recurrence rate seen
in Cushing’s disease indicates a different tumour biology,
which makes surgical cure more difficult.
Theories for hypo-and hyper-cortisolism after surgery
Different theories try to explain why hypocortisolism
is seen after surgery for Cushing’s disease. Hypercorti-
solism, as part of the disease, suppresses the normal
corticotrophes of the pituitary gland, and when the
ACTH-producing tumour is removed, the ACTH level
and, therefore, cortisol decreases to subnormal levels.
The resolution of the suppression of the normal corti-
cotrophes may take as long as 10 to 18 months [21].
If an ACTH-producing tumour is partially resected,
the overproduction of ACTH results in reduced corti-
sol levels that are normalised or even subnormal if
the normal corticotroph cells are supressed. This will
be interpreted as the patient being cured by surgery,
Fig. 3 Mean postoperative S-cortisol values at given hours after surgery. The dense line represents patients who were not in remission at the last
follow-up (68 months) and dotted line represents patients in remission at the last follow-up. Units on the y-axis is nmol/l
Table 3 Pre- and intra-operative findings in relation to the short- and long-term outcome
3 months Long term
In remission Non remission In remission Non remission
n (%) n (%) n (%) n (%)
No. of patients 16 (84) 3 (16) 13 (68) 6 (32)
Macroadenoma 2 (100) 0 1 (50) 1 (50)
Microadenoma 11 (85) 2 (15) 10 (77) 3 (23)
Negative MRI 3 (75) 1 (25) 2 (50) 2 (50)
Histology neg 5 (63) 3 (38) 4 (50) 4 (50)
Mean postoperative S-cortisol nadir 73.44 298.33* 110.15 97.17
*P < 0.05
Ramm-Pettersen et al. BMC Endocrine Disorders  (2015) 15:62 Page 6 of 9
before the tumour regrows and leads to disease recur-
rence. On the other hand, one may argue that the
long standing elevated ACTH levels and, therefore,
severely increased cortisol production from the adre-
nals may result in adrenal hyperplasia that maintains
lasting cortisol hypersecretion even after successful
removal of the ACTH-producing tumour in the pitu-
itary gland [28].
Can cortisol reaching a nadir during the first 3 days after
surgery predict long-term remission?
We wanted to study whether it is possible to establish
distinct criteria for predicting long-term remission early,
within hours to days, after transsphenoidal surgery. In
our series, there was a significant difference in the im-
mediate postoperative S-cortisol nadir between patients
in remission and non-remission at 3 months, which was
not the case at 12 months or at the last follow-up. Two
patients who were not in remission at the three-month
follow-up may explain this; they had late remission that
continued throughout the whole follow-up (patients 4
and 17). On the other hand, five of the patients who
were in early remission had late recurrence (patients 6,
7, 14, 15 and 16). If we exclude the one patient who
never went into remission and look at those five patients
who where in remission at 3 and 12 months, but had
late recurrence of the disease, nothing differed between
them and those who remained in long-term remission.
The method used for evaluating early postoperative cor-
ticotroph function, including serial measurements of S-
cortisol without glucocorticoid substitution, is similar to
the method described in three previously published
studies [14–16]. These studies found that subnormal
postoperative levels of S-cortisol were predictive of sus-
tained remission, but follow-up was a relatively short
(27 months and 33 months) compared to our study
(68 months). We also found that subnormal values of
S-cortisol predicted short-term remission, but subnor-
mal levels did not predict long-term remission.
We have calculated the performance of the nadir
values of postoperative S-cortisol in classifying remis-
sion. We found that the nadir value could be used to
discriminate between remission and non-remission at
3 months with an optimal cut-off at 74 nmol/l. The
ROC curve for long-term remission indicated insignifi-
cant performance. This is in contrast with some other
publications that reported cortisol nadirs as high as
160 nmol/l may be predictive of cure [9], while others
failed to find a specific cut-off level [14, 16]. Even with a
very low cut-off value for the postoperative S-cortisol
Fig. 4 ROC curve demonstrating the performance for the nadir of postoperative S-cortisol in classifying both 3-month and long-term remission.
The areas under the curve for the ROC curves are 0.86 (95 % CI (0.67, 1)) and 0.69 (95 % CI (0.44, 0.93)), respectively
Ramm-Pettersen et al. BMC Endocrine Disorders  (2015) 15:62 Page 7 of 9
nadir, such as 100 nmol/l, that has a high specificity;
there would still have been late recurrence in our study
with 2 out of 19 patients (11 %) after a mean follow-up
of 68 months. Esposito reported a 3 % recurrence rate with
a cut-off at 140 nmol/l in their study and mean 33 months
of follow-up [16]. In our study, two patients achieved long-
term remission in spite of their high postoperative S-
cortisol values and even though they where not in remis-
sion at the 3-month follow-up. With these cut-off values,
they would not have been identified as in remission.
Cortisol has a crucial role in maintaining normal
physiological homeostasis, especially in relation to stress,
and hypocortisolism after surgery may implicate serious
complications, such as Addison’s crisis. Therefore, some
institutions administer glucocorticoids routinely to all
patients undergoing transsphenoidal surgery. For pa-
tients undergoing surgery for Cushing’s disease, we have
chosen to withhold glucocorticoids and followed the
clinical condition closely, while measuring S-cortisol
every sixth hour to detect whether or not the patients
are in remission. It is pertinent to ask whether the bene-
fit of avoiding glucocorticoids in the few patients who
do not need it is worth the risk of the serious hypocorti-
solaemic symptoms. No serious complications have been
reported from well-recognised pituitary centres who use
the same protocol as ours [9, 14–16]. A low postopera-
tive S-cortisol value is certainly gratifying for the sur-
geon, suggesting that adequate surgery has been
performed. If glucocorticoids had been given to all our
patients, we would have given steroids to 7 patients who
were not in need of the medication (4 eucortisolaemic
and 3 hypercortisolaemic). With the relatively high rate
of remission reported in this study, we question whether
it is correct to withhold glucocorticoids after surgery for
Cushing’s disease to detect the few patients who are not
in remission.
ACTH-producing adenomas belong to what is prob-
ably the most challenging subgroup of pituitary aden-
omas, and new techniques like intraoperative MRI and
endonasal endoscopy may help us strive to achieve a
complete resection and improve the outcome after sur-
gery. The use of the histological pseudo-capsule as a
surgical margin is a promising new technique for
achieving radical surgery in pituitary adenomas, origin-
ally presented by Oldfield and Vortmeyer [29]. It has
since been shown that pseudo-capsule resection pro-
duces a faster postoperative decline in cortisol than
piecemeal removal, but it does not have as rapid a de-
cline as seen after hypophysectomy [30]. This elegant
surgical technique can unfortunately only be studied in
a minority of patients, but it will be interesting to see
whether the cure rates can be improved and the long-
term recurrence rate reduced in surgery for Cushing’s
disease.
Conclusion
We achieved a high remission rate with transsphenoidal
surgery for Cushing’s disease in this series of consecutive
patients, and 95 % were in remission at one year. The re-
currence rate was relatively high with a 5-year recur-
rence rate of 26 %, demonstrating the need for thorough
clinical and biochemical follow-up. At 3 months, the
mean S-cortisol nadir was significantly lower in the re-
mission group than in the non-remission group, but low
postoperative S-cortisol did not predict long-term cure.
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